Xilio Therapeutics analyst ratings
Xilio Therapeutics analyst ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/10/2022 | 745.13% | Morgan Stanley | $32 → $20 | Maintains | Overweight |
01/10/2022 | 1421.23% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
11/16/2021 | 1209.95% | Raymond James | → $31 | Initiates Coverage On | → Outperform |
11/16/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
11/16/2021 | 1252.21% | Morgan Stanley | → $32 | Initiates Coverage On | → Overweight |
Xilio Therapeutics Questions & Answers
The latest price target for Xilio Therapeutics (NASDAQ: XLO) was reported by Morgan Stanley on August 10, 2022. The analyst firm set a price target for $20.00 expecting XLO to rise to within 12 months (a possible 745.13% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Xilio Therapeutics (NASDAQ: XLO) was provided by Morgan Stanley, and Xilio Therapeutics maintained their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xilio Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xilio Therapeutics was filed on August 10, 2022 so you should expect the next rating to be made available sometime around August 10, 2023.
While ratings are subjective and will change, the latest Xilio Therapeutics (XLO) rating was a maintained with a price target of $32.00 to $20.00. The current price Xilio Therapeutics (XLO) is trading at is $2.37, which is out of the analyst's predicted range.
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/10/2022 | 745.13% | Morgan Stanley | $32 → $20 | Maintains | Overweight |
01/10/2022 | 1421.23% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
11/16/2021 | 1209.95% | Raymond James | → $31 | Initiates Coverage On | → Outperform |
11/16/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
11/16/2021 | 1252.21% | Morgan Stanley | → $32 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
---|---|---|---|---|---|
08/10/2022 | 745.13% | 摩根士丹利 | $32 → $20 | 維護 | 超重 |
01/10/2022 | 1421.23% | HC Wainwright公司 | → $36 | 開始承保 | →購買 |
11/16/2021 | 1209.95% | 雷蒙德·詹姆斯 | → $31 | 開始承保 | →跑贏大盤 |
11/16/2021 | — | 考恩公司 | 開始承保 | →跑贏大盤 | |
11/16/2021 | 1252.21% | 摩根士丹利 | → $32 | 開始承保 | →超重 |
Xilio Therapeutics Questions & Answers
西里奧治療學問答
The latest price target for Xilio Therapeutics (NASDAQ: XLO) was reported by Morgan Stanley on August 10, 2022. The analyst firm set a price target for $20.00 expecting XLO to rise to within 12 months (a possible 745.13% upside). 5 analyst firms have reported ratings in the last year.
納斯達克(納斯達克代碼:XLO)的最新目標價是由摩根士丹利於2022年8月10日報道的。這家分析公司將目標價定為20美元,預計XLO將在12個月內升至(可能上漲745.13%)。去年有5家分析公司公佈了評級。
The latest analyst rating for Xilio Therapeutics (NASDAQ: XLO) was provided by Morgan Stanley, and Xilio Therapeutics maintained their overweight rating.
納斯達克(Sequoia Capital:XLO)的最新分析師評級由摩根士丹利提供,喜力治療維持增持評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xilio Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xilio Therapeutics was filed on August 10, 2022 so you should expect the next rating to be made available sometime around August 10, 2023.
分析師在進行了廣泛的研究後得出了股票評級,其中包括查閲公共財務報表,與希利奧治療公司的高管和客户交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Xilio治療公司的上一次評級是在2022年8月10日提交的,所以你應該預計下一次評級將在2023年8月10日左右的某個時候提供。
While ratings are subjective and will change, the latest Xilio Therapeutics (XLO) rating was a maintained with a price target of $32.00 to $20.00. The current price Xilio Therapeutics (XLO) is trading at is $2.37, which is out of the analyst's predicted range.
雖然評級是主觀的,並將發生變化,但最新的Xilio治療公司(XLO)評級保持不變,目標價在32.00美元至20.00美元之間。希利奧治療公司(XLO)目前的交易價格為2.37美元,超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧